# Olaparib in Patients With HRD Malignant Mesothelioma

> **NCT04515836** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 56 (estimated)

## Conditions studied

- Mesothelioma
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04515836
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-19
- **Primary completion:** 2028-04-15
- **Final completion:** 2028-04-15
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515836, "Olaparib in Patients With HRD Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04515836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*